Glycomic Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Description

The global glycomic therapeutics market is on the verge of substantial growth according to the latest market research report by Fairfield Market Research. This surge is expected to elevate the market's estimated valuation to US$ 541 Billion by 2031, a significant increase from US$ 180 Billion in 2024.

Key Market Drivers for Glycomic Therapeutics Market

The glycomic therapeutics market is driven by several pivotal factors, including:

1. Advanced Cancer Diagnosis: The need for more accessible methods for cancer diagnosis is a key driver. Glycomic therapeutics offer promising avenues for early and accurate cancer detection.
2. Antimicrobial Vaccines: Development in antimicrobial vaccines is fostering the demand for glycomic therapeutics, as they play a vital role in combatting infectious diseases.
3. Advancements in Drug Development: The market is benefiting from continuous advancements in drug development, with glycomics at the forefront of innovative pharmaceutical research.
4. Integration of AI and Data Analytics: The integration of Artificial Intelligence (AI) and data analytics is set to be a significant contributor to market growth, facilitating data-driven insights and personalized treatment strategies.
5. Mass Spectrometry: Researchers emphasize the transformative potential of mass spectrometry as a powerful tool in glycomic therapeutics, driving innovation and discovery in the field.
6. Research and Development Investments: Increased investments in research and development by industry leaders and governments are further propelling market growth, fostering innovation and expansion.

Challenges and Restraints

Despite its promising outlook, the glycomic therapeutics market faces certain challenges, including:

1. High Costs: The high cost associated with procedures such as mass spectrometry is a significant restraint, limiting accessibility for some patient populations.
2. Shortage of Skilled Professionals: A shortage of skilled professionals in the field, partly due to limited awareness, hampers the market's growth potential.

Opportunities through Collaborations

The report highlights a surge in collaborations between academic and research institutes, driving innovation in glycomic therapeutics. These partnerships are instrumental in Research and Development (R&D) efforts to create new therapeutic methods. Additionally, the adoption of glycomics for educational purposes is expected to stimulate market growth.

Regional Insights

USA: The United States is poised to emerge as the largest market for glycomic therapeutics. Its technologically advanced healthcare sector and awareness initiatives make it a hotspot for market growth.

Europe: Europe presents a substantial market, driven by collaborations between research and academic institutions. The region's high prevalence of cancer patients offers significant opportunities, particularly in cancer detection.

Japan: Japan, renowned for technological advancements and genetic research, offers considerable potential for the glycomic therapeutics market. The country's focus on personalized medication aligns with market growth.

South Korea: South Korea is experiencing dynamic growth in the glycomic therapeutics market, buoyed by an influx of skilled professionals and increasing demand for glycomic therapeutics.

key companies profiled in the glycomic therapeutics market:

Intellihep
Protalix Biotherapeutics
BioMarin Pharmaceutical
Genzyme Corporation
Halozyme Therapeutics
Bayer AG
Alzheon
GlycoMar
GlaxoSmithKline
F. Hoffmann-La Roche

Glycomic Therapeutics Market Segmentation

By Class:

Isolated
Synthetic

By Structures:

Glycoproteins
Targeting Sialic Acid
Proteoglycans
Targeting Glycosaminoglycans
Targeting Glycosylphosphatidylinositol (GPI) - Anchored Proteins and Heparin Based Glycans
Targeting Glycosphingolipids
Others

By Indications:

Thrombosis and Chemoprophylaxis
Anaemia
Anti-adhesive and Anti-inflammatory
Cataracts
Gaucher's disease
MPS-1 and IV
Cancer
Alzheimer's disease
Influenza type A and B
Others

By Mode of Action:

Inhibits Neuraminidase
Inhibits Heparanase and Selectins and Blocks Interactions between Growth Factors and Heparan Sulfate
Erythropoietin and Enzyme Replacement Therapy
Tissue Plasminogen Activator
Inhibits Glucosylceramide Synthase
Interleukin 1, 2 & 3
Beta and Gamma Interferons
Others

By Region:

North America
Latin America
Asia Pacific
MEA
Europe

1. Executive Summary

1.1. Global Glycomic Therapeutics Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
- 2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Glycomic Therapeutics Market Outlook, 2018 - 2031

3.1. Global Glycomic Therapeutics Market Outlook, by Class, Value (US$ Bn), 2018 - 2031
- 3.1.1. Key Highlights
  - 3.1.1.1. Isolated
  - 3.1.1.2. Synthetic
3.2. Global Glycomic Therapeutics Market Outlook, by Structure, Value (US$ Bn), 2018 - 2031
- 3.2.1. Key Highlights
  - 3.2.1.1. Glycoproteins
  - 3.2.1.2. Targeting Sialic Acid
  - 3.2.1.3. Proteoglycans
  - 3.2.1.4. Targeting Glycosaminoglycans
  - 3.2.1.5. Targeting Glycosylphosphatidylinositol (GPI) - Anchored Proteins and Heparin Based Glycans
  - 3.2.1.6. Targeting Glycosphingolipids
  - 3.2.1.7. Others
3.3. Global Glycomic Therapeutics Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
- 3.3.1. Key Highlights
  - 3.3.1.1. Thrombosis and Chemoprophylaxis
  - 3.3.1.2. Anaemia
  - 3.3.1.3. Anti-adhesive and Anti-inflammatory
  - 3.3.1.4. Cataracts
  - 3.3.1.5. Gaucher's disease
  - 3.3.1.6. MPS-1 and IV
  - 3.3.1.7. Cancer
  - 3.3.1.8. Alzheimer's disease
  - 3.3.1.9. Influenza type A and B
  - 3.3.1.10. Others
3.4. Global Glycomic Therapeutics Market Outlook, by Mode of Action, Value (US$ Bn), 2018 - 2031
- 3.4.1. Key Highlights
  - 3.4.1.1. Inhibits Neuraminidase
  - 3.4.1.2. Inhibits Heparanase and Selectins and Blocks Interactions between Growth Factors and Heparan Sulfate
  - 3.4.1.3. Erythropoietin and Enzyme Replacement Therapy
  - 3.4.1.4. Tissue Plasminogen Activator
  - 3.4.1.5. Inhibits Glucosylceramide Synthase
  - 3.4.1.6. Interleukin 1, 2 & 3
  - 3.4.1.7. Beta and Gamma Interferons
  - 3.4.1.8. Others
3.5. Global Glycomic Therapeutics Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
- 3.5.1. Key Highlights
  - 3.5.1.1. North America
  - 3.5.1.2. Europe
  - 3.5.1.3. Asia Pacific
  - 3.5.1.4. Latin America
  - 3.5.1.5. Middle East & Africa

4. North America Glycomic Therapeutics Market Outlook, 2018 - 2031

4.1. North America Glycomic Therapeutics Market Outlook, by Class, Value (US$ Bn), 2018 - 2031
- 4.1.1. Key Highlights
  - 4.1.1.1. Isolated
  - 4.1.1.2. Synthetic
4.2. North America Glycomic Therapeutics Market Outlook, by Structure, Value (US$ Bn), 2018 - 2031
- 4.2.1. Key Highlights
  - 4.2.1.1. Glycoproteins
  - 4.2.1.2. Targeting Sialic Acid
  - 4.2.1.3. Proteoglycans
  - 4.2.1.4. Targeting Glycosaminoglycans
  - 4.2.1.5. Targeting Glycosylphosphatidylinositol (GPI) - Anchored Proteins and Heparin Based Glycans
  - 4.2.1.6. Targeting Glycosphingolipids
  - 4.2.1.7. Others
4.3. North America Glycomic Therapeutics Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
- 4.3.1. Key Highlights
  - 4.3.1.1. Thrombosis and Chemoprophylaxis
  - 4.3.1.2. Anaemia
  - 4.3.1.3. Anti-adhesive and Anti-inflammatory
  - 4.3.1.4. Cataracts
  - 4.3.1.5. Gaucher's disease
  - 4.3.1.6. MPS-1 and IV
  - 4.3.1.7. Cancer
  - 4.3.1.8. Alzheimer's disease
  - 4.3.1.9. Influenza type A and B
  - 4.3.1.10. Others
4.4. North America Glycomic Therapeutics Market Outlook, by Mode of Action, Value (US$ Bn), 2018 - 2031
- 4.4.1. Key Highlights
  - 4.4.1.1. Inhibits Neuraminidase
  - 4.4.1.2. Inhibits Heparanase and Selectins and Blocks Interactions between Growth Factors and Heparan Sulfate
  - 4.4.1.3. Erythropoietin and Enzyme Replacement Therapy
  - 4.4.1.4. Tissue Plasminogen Activator
  - 4.4.1.5. Inhibits Glucosylceramide Synthase
  - 4.4.1.6. Interleukin 1, 2 & 3
  - 4.4.1.7. Beta and Gamma Interferons
  - 4.4.1.8. Others
4.5. North America Glycomic Therapeutics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 4.5.1. Key Highlights
  - 4.5.1.1. U.S. Glycomic Therapeutics Market by Class, Value (US$ Bn), 2018 - 2031
  - 4.5.1.2. U.S. Glycomic Therapeutics Market By Structure, Value (US$ Bn), 2018 - 2031
  - 4.5.1.3. U.S. Glycomic Therapeutics Market By Indication, Value (US$ Bn), 2018 - 2031
  - 4.5.1.4. U.S. Glycomic Therapeutics Market By Mode of Action, Value (US$ Bn), 2018 - 2031
  - 4.5.1.5. Canada Glycomic Therapeutics Market by Class, Value (US$ Bn), 2018 - 2031
  - 4.5.1.6. Canada Glycomic Therapeutics Market By Structure, Value (US$ Bn), 2018 - 2031
  - 4.5.1.7. Canada Glycomic Therapeutics Market By Indication, Value (US$ Bn), 2018 - 2031
  - 4.5.1.8. Canada Glycomic Therapeutics Market By Mode of Action, Value (US$ Bn), 2018 - 2031
- 4.5.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Glycomic Therapeutics Market Outlook, 2018 - 2031

5.1. Europe Glycomic Therapeutics Market Outlook, by Class, Value (US$ Bn), 2018 - 2031
- 5.1.1. Key Highlights
  - 5.1.1.1. Isolated
  - 5.1.1.2. Synthetic
5.2. Europe Glycomic Therapeutics Market Outlook, by Structure, Value (US$ Bn), 2018 - 2031
- 5.2.1. Key Highlights
  - 5.2.1.1. Glycoproteins
  - 5.2.1.2. Targeting Sialic Acid
  - 5.2.1.3. Proteoglycans
  - 5.2.1.4. Targeting Glycosaminoglycans
  - 5.2.1.5. Targeting Glycosylphosphatidylinositol (GPI) - Anchored Proteins and Heparin Based Glycans
  - 5.2.1.6. Targeting Glycosphingolipids
  - 5.2.1.7. Others
5.3. Europe Glycomic Therapeutics Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
- 5.3.1. Key Highlights
  - 5.3.1.1. Thrombosis and Chemoprophylaxis
  - 5.3.1.2. Anaemia
  - 5.3.1.3. Anti-adhesive and Anti-inflammatory
  - 5.3.1.4. Cataracts
  - 5.3.1.5. Gaucher's disease
  - 5.3.1.6. MPS-1 and IV
  - 5.3.1.7. Cancer
  - 5.3.1.8. Alzheimer's disease
  - 5.3.1.9. Influenza type A and B
  - 5.3.1.10. Others
5.4. Europe Glycomic Therapeutics Market Outlook, by Mode of Action, Value (US$ Bn), 2018 - 2031
- 5.4.1. Key Highlights
  - 5.4.1.1. Inhibits Neuraminidase
  - 5.4.1.2. Inhibits Heparanase and Selectins and Blocks Interactions between Growth Factors and Heparan Sulfate
  - 5.4.1.3. Erythropoietin and Enzyme Replacement Therapy
  - 5.4.1.4. Tissue Plasminogen Activator
  - 5.4.1.5. Inhibits Glucosylceramide Synthase
  - 5.4.1.6. Interleukin 1, 2 & 3
  - 5.4.1.7. Beta and Gamma Interferons
  - 5.4.1.8. Others
5.5. Europe Glycomic Therapeutics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 5.5.1. Key Highlights
  - 5.5.1.1. Germany Glycomic Therapeutics Market by Class, Value (US$ Bn), 2018 - 2031
  - 5.5.1.2. Germany Glycomic Therapeutics Market By Structure, Value (US$ Bn), 2018 - 2031
  - 5.5.1.3. Germany Glycomic Therapeutics Market By Indication, Value (US$ Bn), 2018 - 2031
  - 5.5.1.4. Germany Glycomic Therapeutics Market By Mode of Action, Value (US$ Bn), 2018 - 2031
  - 5.5.1.5. U.K. Glycomic Therapeutics Market by Class, Value (US$ Bn), 2018 - 2031
  - 5.5.1.6. U.K. Glycomic Therapeutics Market By Structure, Value (US$ Bn), 2018 - 2031
  - 5.5.1.7. U.K. Glycomic Therapeutics Market By Indication, Value (US$ Bn), 2018 - 2031
  - 5.5.1.8. U.K. Glycomic Therapeutics Market By Mode of Action, Value (US$ Bn), 2018 - 2031
  - 5.5.1.9. France Glycomic Therapeutics Market by Class, Value (US$ Bn), 2018 - 2031
  - 5.5.1.10. France Glycomic Therapeutics Market By Structure, Value (US$ Bn), 2018 - 2031
  - 5.5.1.11. France Glycomic Therapeutics Market By Indication, Value (US$ Bn), 2018 - 2031
  - 5.5.1.12. France Glycomic Therapeutics Market By Mode of Action, Value (US$ Bn), 2018 - 2031
  - 5.5.1.13. Italy Glycomic Therapeutics Market by Class, Value (US$ Bn), 2018 - 2031
  - 5.5.1.14. Italy Glycomic Therapeutics Market By Structure, Value (US$ Bn), 2018 - 2031
  - 5.5.1.15. Italy Glycomic Therapeutics Market By Indication, Value (US$ Bn), 2018 - 2031
  - 5.5.1.16. Italy Glycomic Therapeutics Market By Mode of Action, Value (US$ Bn), 2018 - 2031
  - 5.5.1.17. Turkey Glycomic Therapeutics Market by Class, Value (US$ Bn), 2018 - 2031
  - 5.5.1.18. Turkey Glycomic Therapeutics Market By Structure, Value (US$ Bn), 2018 - 2031
  - 5.5.1.19. Turkey Glycomic Therapeutics Market By Indication, Value (US$ Bn), 2018 - 2031
  - 5.5.1.20. Turkey Glycomic Therapeutics Market By Mode of Action, Value (US$ Bn), 2018 - 2031
  - 5.5.1.21. Russia Glycomic Therapeutics Market by Class, Value (US$ Bn), 2018 - 2031
  - 5.5.1.22. Russia Glycomic Therapeutics Market By Structure, Value (US$ Bn), 2018 - 2031
  - 5.5.1.23. Russia Glycomic Therapeutics Market By Indication, Value (US$ Bn), 2018 - 2031
  - 5.5.1.24. Russia Glycomic Therapeutics Market By Mode of Action, Value (US$ Bn), 2018 - 2031
  - 5.5.1.25. Rest of Europe Glycomic Therapeutics Market by Class, Value (US$ Bn), 2018 - 2031
  - 5.5.1.26. Rest of Europe Glycomic Therapeutics Market By Structure, Value (US$ Bn), 2018 - 2031
  - 5.5.1.27. Rest of Europe Glycomic Therapeutics Market By Indication, Value (US$ Bn), 2018 - 2031
  - 5.5.1.28. Rest of Europe Glycomic Therapeutics Market By Mode of Action, Value (US$ Bn), 2018 - 2031
- 5.5.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Glycomic Therapeutics Market Outlook, 2018 - 2031

6.1. Asia Pacific Glycomic Therapeutics Market Outlook, by Class, Value (US$ Bn), 2018 - 2031
- 6.1.1. Key Highlights
  - 6.1.1.1. Isolated
  - 6.1.1.2. Synthetic
6.2. Asia Pacific Glycomic Therapeutics Market Outlook, by Structure, Value (US$ Bn), 2018 - 2031
- 6.2.1. Key Highlights
  - 6.2.1.1. Glycoproteins
  - 6.2.1.2. Targeting Sialic Acid
  - 6.2.1.3. Proteoglycans
  - 6.2.1.4. Targeting Glycosaminoglycans
  - 6.2.1.5. Targeting Glycosylphosphatidylinositol (GPI) - Anchored Proteins and Heparin Based Glycans
  - 6.2.1.6. Targeting Glycosphingolipids
  - 6.2.1.7. Others
6.3. Asia Pacific Glycomic Therapeutics Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
- 6.3.1. Key Highlights
  - 6.3.1.1. Thrombosis and Chemoprophylaxis
  - 6.3.1.2. Anaemia
  - 6.3.1.3. Anti-adhesive and Anti-inflammatory
  - 6.3.1.4. Cataracts
  - 6.3.1.5. Gaucher's disease
  - 6.3.1.6. MPS-1 and IV
  - 6.3.1.7. Cancer
  - 6.3.1.8. Alzheimer's disease
  - 6.3.1.9. Influenza type A and B
  - 6.3.1.10. Others
6.4. Asia Pacific Glycomic Therapeutics Market Outlook, by Mode of Action, Value (US$ Bn), 2018 - 2031
- 6.4.1. Key Highlights
  - 6.4.1.1. Inhibits Neuraminidase
  - 6.4.1.2. Inhibits Heparanase and Selectins and Blocks Interactions between Growth Factors and Heparan Sulfate
  - 6.4.1.3. Erythropoietin and Enzyme Replacement Therapy
  - 6.4.1.4. Tissue Plasminogen Activator
  - 6.4.1.5. Inhibits Glucosylceramide Synthase
  - 6.4.1.6. Interleukin 1, 2 & 3
  - 6.4.1.7. Beta and Gamma Interferons
  - 6.4.1.8. Others
6.5. Asia Pacific Glycomic Therapeutics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 6.5.1. Key Highlights
  - 6.5.1.1. China Glycomic Therapeutics Market by Class, Value (US$ Bn), 2018 - 2031
  - 6.5.1.2. China Glycomic Therapeutics Market By Structure, Value (US$ Bn), 2018 - 2031
  - 6.5.1.3. China Glycomic Therapeutics Market By Indication, Value (US$ Bn), 2018 - 2031
  - 6.5.1.4. China Glycomic Therapeutics Market By Mode of Action, Value (US$ Bn), 2018 - 2031
  - 6.5.1.5. Japan Glycomic Therapeutics Market by Class, Value (US$ Bn), 2018 - 2031
  - 6.5.1.6. Japan Glycomic Therapeutics Market By Structure, Value (US$ Bn), 2018 - 2031
  - 6.5.1.7. Japan Glycomic Therapeutics Market By Indication, Value (US$ Bn), 2018 - 2031
  - 6.5.1.8. Japan Glycomic Therapeutics Market By Mode of Action, Value (US$ Bn), 2018 - 2031
  - 6.5.1.9. South Korea Glycomic Therapeutics Market by Class, Value (US$ Bn), 2018 - 2031
  - 6.5.1.10. South Korea Glycomic Therapeutics Market By Structure, Value (US$ Bn), 2018 - 2031
  - 6.5.1.11. South Korea Glycomic Therapeutics Market By Indication, Value (US$ Bn), 2018 - 2031
  - 6.5.1.12. South Korea Glycomic Therapeutics Market By Mode of Action, Value (US$ Bn), 2018 - 2031
  - 6.5.1.13. India Glycomic Therapeutics Market by Class, Value (US$ Bn), 2018 - 2031
  - 6.5.1.14. India Glycomic Therapeutics Market By Structure, Value (US$ Bn), 2018 - 2031
  - 6.5.1.15. India Glycomic Therapeutics Market By Indication, Value (US$ Bn), 2018 - 2031
  - 6.5.1.16. India Glycomic Therapeutics Market By Mode of Action, Value (US$ Bn), 2018 - 2031
  - 6.5.1.17. Southeast Asia Glycomic Therapeutics Market by Class, Value (US$ Bn), 2018 - 2031
  - 6.5.1.18. Southeast Asia Glycomic Therapeutics Market By Structure, Value (US$ Bn), 2018 - 2031
  - 6.5.1.19. Southeast Asia Glycomic Therapeutics Market By Indication, Value (US$ Bn), 2018 - 2031
  - 6.5.1.20. Southeast Asia Glycomic Therapeutics Market By Mode of Action, Value (US$ Bn), 2018 - 2031
  - 6.5.1.21. Rest of Asia Pacific Glycomic Therapeutics Market by Class, Value (US$ Bn), 2018 - 2031
  - 6.5.1.22. Rest of Asia Pacific Glycomic Therapeutics Market By Structure, Value (US$ Bn), 2018 - 2031
  - 6.5.1.23. Rest of Asia Pacific Glycomic Therapeutics Market By Indication, Value (US$ Bn), 2018 - 2031
  - 6.5.1.24. Rest of Asia Pacific Glycomic Therapeutics Market By Mode of Action, Value (US$ Bn), 2018 - 2031
- 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Glycomic Therapeutics Market Outlook, 2018 - 2031

7.1. Latin America Glycomic Therapeutics Market Outlook, by Class, Value (US$ Bn), 2018 - 2031
- 7.1.1. Key Highlights
  - 7.1.1.1. Isolated
  - 7.1.1.2. Synthetic
7.2. Latin America Glycomic Therapeutics Market Outlook, by Structure, Value (US$ Bn), 2018 - 2031
7.3. Latin America Glycomic Therapeutics Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
- 7.3.1. Key Highlights
  - 7.3.1.1. Thrombosis and Chemoprophylaxis
  - 7.3.1.2. Anaemia
  - 7.3.1.3. Anti-adhesive and Anti-inflammatory
  - 7.3.1.4. Cataracts
  - 7.3.1.5. Gaucher's disease
  - 7.3.1.6. MPS-1 and IV
  - 7.3.1.7. Cancer
  - 7.3.1.8. Alzheimer's disease
  - 7.3.1.9. Influenza type A and B
  - 7.3.1.10. Others
7.4. Latin America Glycomic Therapeutics Market Outlook, by Mode of Action, Value (US$ Bn), 2018 - 2031
- 7.4.1. Key Highlights
  - 7.4.1.1. Inhibits Neuraminidase
  - 7.4.1.2. Inhibits Heparanase and Selectins and Blocks Interactions between Growth Factors and Heparan Sulfate
  - 7.4.1.3. Erythropoietin and Enzyme Replacement Therapy
  - 7.4.1.4. Tissue Plasminogen Activator
  - 7.4.1.5. Inhibits Glucosylceramide Synthase
  - 7.4.1.6. Interleukin 1, 2 & 3
  - 7.4.1.7. Beta and Gamma Interferons
  - 7.4.1.8. Others
7.5. Latin America Glycomic Therapeutics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 7.5.1. Key Highlights
  - 7.5.1.1. Brazil Glycomic Therapeutics Market by Class, Value (US$ Bn), 2018 - 2031
  - 7.5.1.2. Brazil Glycomic Therapeutics Market By Structure, Value (US$ Bn), 2018 - 2031
  - 7.5.1.3. Brazil Glycomic Therapeutics Market By Indication, Value (US$ Bn), 2018 - 2031
  - 7.5.1.4. Brazil Glycomic Therapeutics Market By Mode of Action, Value (US$ Bn), 2018 - 2031
  - 7.5.1.5. Mexico Glycomic Therapeutics Market by Class, Value (US$ Bn), 2018 - 2031
  - 7.5.1.6. Mexico Glycomic Therapeutics Market By Structure, Value (US$ Bn), 2018 - 2031
  - 7.5.1.7. Mexico Glycomic Therapeutics Market By Indication, Value (US$ Bn), 2018 - 2031
  - 7.5.1.8. Mexico Glycomic Therapeutics Market By Mode of Action, Value (US$ Bn), 2018 - 2031
  - 7.5.1.9. Argentina Glycomic Therapeutics Market by Class, Value (US$ Bn), 2018 - 2031
  - 7.5.1.10. Argentina Glycomic Therapeutics Market By Structure, Value (US$ Bn), 2018 - 2031
  - 7.5.1.11. Argentina Glycomic Therapeutics Market By Indication, Value (US$ Bn), 2018 - 2031
  - 7.5.1.12. Argentina Glycomic Therapeutics Market By Mode of Action, Value (US$ Bn), 2018 - 2031
  - 7.5.1.13. Rest of Latin America Glycomic Therapeutics Market by Class, Value (US$ Bn), 2018 - 2031
  - 7.5.1.14. Rest of Latin America Glycomic Therapeutics Market By Structure, Value (US$ Bn), 2018 - 2031
  - 7.5.1.15. Rest of Latin America Glycomic Therapeutics Market By Indication, Value (US$ Bn), 2018 - 2031
  - 7.5.1.16. Rest of Latin America Glycomic Therapeutics Market By Mode of Action, Value (US$ Bn), 2018 - 2031
- 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Glycomic Therapeutics Market Outlook, 2018 - 2031

8.1. Middle East & Africa Glycomic Therapeutics Market Outlook, by Class, Value (US$ Bn), 2018 - 2031
- 8.1.1. Key Highlights
  - 8.1.1.1. Isolated
  - 8.1.1.2. Synthetic
8.2. Middle East & Africa Glycomic Therapeutics Market Outlook, by Structure, Value (US$ Bn), 2018 - 2031
- 8.2.1. Key Highlights
  - 8.2.1.1. Glycoproteins
  - 8.2.1.2. Targeting Sialic Acid
  - 8.2.1.3. Proteoglycans
  - 8.2.1.4. Targeting Glycosaminoglycans
  - 8.2.1.5. Targeting Glycosylphosphatidylinositol (GPI) - Anchored Proteins and Heparin Based Glycans
  - 8.2.1.6. Targeting Glycosphingolipids
  - 8.2.1.7. Others
8.3. Middle East & Africa Glycomic Therapeutics Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
- 8.3.1. Key Highlights
  - 8.3.1.1. Thrombosis and Chemoprophylaxis
  - 8.3.1.2. Anaemia
  - 8.3.1.3. Anti-adhesive and Anti-inflammatory
  - 8.3.1.4. Cataracts
  - 8.3.1.5. Gaucher's disease
  - 8.3.1.6. MPS-1 and IV
  - 8.3.1.7. Cancer
  - 8.3.1.8. Alzheimer's disease
  - 8.3.1.9. Influenza type A and B
  - 8.3.1.10. Others
8.4. Middle East & Africa Glycomic Therapeutics Market Outlook, by Mode of Action, Value (US$ Bn), 2018 - 2031
- 8.4.1. Key Highlights
  - 8.4.1.1. Inhibits Neuraminidase
  - 8.4.1.2. Inhibits Heparanase and Selectins and Blocks Interactions between Growth Factors and Heparan Sulfate
  - 8.4.1.3. Erythropoietin and Enzyme Replacement Therapy
  - 8.4.1.4. Tissue Plasminogen Activator
  - 8.4.1.5. Inhibits Glucosylceramide Synthase
  - 8.4.1.6. Interleukin 1, 2 & 3
  - 8.4.1.7. Beta and Gamma Interferons
  - 8.4.1.8. Others
8.5. Middle East & Africa Glycomic Therapeutics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 8.5.1. Key Highlights
  - 8.5.1.1. GCC Glycomic Therapeutics Market by Class, Value (US$ Bn), 2018 - 2031
  - 8.5.1.2. GCC Glycomic Therapeutics Market By Structure, Value (US$ Bn), 2018 - 2031
  - 8.5.1.3. GCC Glycomic Therapeutics Market By Indication, Value (US$ Bn), 2018 - 2031
  - 8.5.1.4. GCC Glycomic Therapeutics Market By Mode of Action, Value (US$ Bn), 2018 - 2031
  - 8.5.1.5. South Africa Glycomic Therapeutics Market by Class, Value (US$ Bn), 2018 - 2031
  - 8.5.1.6. South Africa Glycomic Therapeutics Market By Structure, Value (US$ Bn), 2018 - 2031
  - 8.5.1.7. South Africa Glycomic Therapeutics Market By Indication, Value (US$ Bn), 2018 - 2031
  - 8.5.1.8. South Africa Glycomic Therapeutics Market By Mode of Action, Value (US$ Bn), 2018 - 2031
  - 8.5.1.9. Egypt Glycomic Therapeutics Market by Class, Value (US$ Bn), 2018 - 2031
  - 8.5.1.10. Egypt Glycomic Therapeutics Market By Structure, Value (US$ Bn), 2018 - 2031
  - 8.5.1.11. Egypt Glycomic Therapeutics Market By Indication, Value (US$ Bn), 2018 - 2031
  - 8.5.1.12. Egypt Glycomic Therapeutics Market By Mode of Action, Value (US$ Bn), 2018 - 2031
  - 8.5.1.13. Nigeria Glycomic Therapeutics Market by Class, Value (US$ Bn), 2018 - 2031
  - 8.5.1.14. Nigeria Glycomic Therapeutics Market By Structure, Value (US$ Bn), 2018 - 2031
  - 8.5.1.15. Nigeria Glycomic Therapeutics Market By Indication, Value (US$ Bn), 2018 - 2031
  - 8.5.1.16. Nigeria Glycomic Therapeutics Market By Mode of Action, Value (US$ Bn), 2018 - 2031
  - 8.5.1.17. Rest of Middle East & Africa Glycomic Therapeutics Market by Class, Value (US$ Bn), 2018 - 2031
  - 8.5.1.18. Rest of Middle East & Africa Glycomic Therapeutics Market By Structure, Value (US$ Bn), 2018 - 2031
  - 8.5.1.19. Rest of Middle East & Africa Glycomic Therapeutics Market By Indication, Value (US$ Bn), 2018 - 2031
  - 8.5.1.20. Rest of Middle East & Africa Glycomic Therapeutics Market By Mode of Action, Value (US$ Bn), 2018 - 2031
- 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. By Indication vs By Structure Heatmap
9.2. Manufacturer vs By Structure Heatmap
9.3. Company Market Share Analysis, 2023
9.4. Competitive Dashboard
9.5. Company Profiles
- 9.5.1. Intellihep
  - 9.5.1.1. Company Overview
  - 9.5.1.2. Product Portfolio
  - 9.5.1.3. Financial Overview
  - 9.5.1.4. Business Strategies and Development
- 9.5.2. Protalix Biotherapeutics
  - 9.5.2.1. Company Overview
  - 9.5.2.2. Product Portfolio
  - 9.5.2.3. Financial Overview
  - 9.5.2.4. Business Strategies and Development
- 9.5.3. BioMarin Pharmaceutical
  - 9.5.3.1. Company Overview
  - 9.5.3.2. Product Portfolio
  - 9.5.3.3. Financial Overview
  - 9.5.3.4. Business Strategies and Development
- 9.5.4. Genzyme Corporation
  - 9.5.4.1. Company Overview
  - 9.5.4.2. Product Portfolio
  - 9.5.4.3. Financial Overview
  - 9.5.4.4. Business Strategies and Development
- 9.5.5. Halozyme Therapeutics
  - 9.5.5.1. Company Overview
  - 9.5.5.2. Product Portfolio
  - 9.5.5.3. Financial Overview
  - 9.5.5.4. Business Strategies and Development
- 9.5.6. Bayer AG
  - 9.5.6.1. Company Overview
  - 9.5.6.2. Product Portfolio
  - 9.5.6.3. Financial Overview
  - 9.5.6.4. Business Strategies and Development
- 9.5.7. Alzheon
  - 9.5.7.1. Company Overview
  - 9.5.7.2. Product Portfolio
  - 9.5.7.3. Financial Overview
  - 9.5.7.4. Business Strategies and Development
- 9.5.8. GlycoMar
  - 9.5.8.1. Company Overview
  - 9.5.8.2. Product Portfolio
  - 9.5.8.3. Financial Overview
  - 9.5.8.4. Business Strategies and Development
- 9.5.9. GlaxoSmithKline
  - 9.5.9.1. Company Overview
  - 9.5.9.2. Product Portfolio
  - 9.5.9.3. Financial Overview
  - 9.5.9.4. Business Strategies and Development
- 9.5.10. F. Hoffmann-La Roche
  - 9.5.10.1. Company Overview
  - 9.5.10.2. Product Portfolio
  - 9.5.10.3. Financial Overview
  - 9.5.10.4. Business Strategies and Development

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations